ArticleFrontiers in oncology2026
The development and validation of a machine learning algorithm for identifying lateral lymph nodes skip metastasis in papillary thyroid cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Skip metastasis from papillary thyroid cancer (PTC) is often unpredictable and characterized by lateral lymph node metastasis without central lymph node metastasis. Our objective was to provide a predictive model for skip metastases to cervical lymph nodes based on clinical and demographic data using machine learning. Materials and methods: From January 2016 to December 2021, patients who underwent thyroidectomy, central lymph node dissection, and lateral lymph node dissection at the Department of Thyroid Surgery at our hospital, had their clinical and pathological data analyzed retrospectively. Following the identification of five critical characteristics, six machine learning models were developed. Accuracy, sensitivity, specificity, positive predictive value, negative predictive value, F1 score, kappa statistics, and area under the curve were measured in the performance evaluation process, and decision curve analysis was used to determine the clinical advantage. Next, universality was assessed through internal validation. R and Python software was used for all statistical analyses and model construction. Results: The incidence of skip lymph node metastases was 13.02% (47/361). Pertinent elements encompassed the number of nodes removed as a result of central lymph node dissection, the existence or non-existence of Hashimoto thyroiditis, the largest tumour size, its bilateral nature, and its multifocal nature. By outperforming alternative models, the random forest model demonstrated excellent performance on the internal validation cohort. Conclusion: This study focused on identifying the risk factors associated with skip metastasis, with the aim of developing an efficient predictive model for this condition using readily available clinical variables. This model can precisely identify skip metastases in PTC using an uncomplicated approach, offering promise for routine clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.